quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anal Cancer
Conditions
Anal Cancer, Nonneoplastic Condition, Penile Cancer, Precancerous Condition
Trial Timeline
Jun 28, 2011 → Dec 12, 2017
NCT ID
NCT01209325About quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine is a phase 2 stage product being developed by Merck for Anal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01209325. Target conditions include Anal Cancer, Nonneoplastic Condition, Penile Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01209325 | Phase 2 | Completed |
| NCT00733122 | Phase 3 | Withdrawn |
| NCT00635830 | Phase 1 | Completed |
| NCT00380367 | Phase 3 | Completed |
Competing Products
20 competing products in Anal Cancer